Email this article Enhancement of interferon treatment for large basaliomas
- Authors: Molochkov A.V.1, Rumyantsev S.A.2, Khlebnikova A.N.3
-
Affiliations:
- Moscow Regional Research and Clinical Institute (MONIKI)
- Vologda Regional Clinic for Skin and Venereal Diseases
- M. Sechenov First Moscow State Medical University
- Issue: Vol 45, No 4 (2017)
- Pages: 314-320
- Section: ARTICLES
- URL: https://almclinmed.ru/jour/article/view/563
- DOI: https://doi.org/10.18786/2072-0505-2017-45-4-314-320
- ID: 563
Cite item
Full Text
Abstract
Background: Treatment of large basaliomas may be problematic, because relapses after the use of various treatment modalities are frequent.
Aim: To assess the efficacy of interferon therapy for primary solitary T2N0M0 basalioma.
Materials and methods: We retrospectively analyzed the results of treatment of 72 patients with primary solitary basalioma T2N0M0. The patients from the main group (n = 35) were treated with injections of recombinant interferon alfa 2b into the lesion at a dose of 2 to 3 Mio IU (total dose for the treatment course from 18 to 27 Mio IU). The reference group included 37 patients treated by cryodestruction. The results were assessed at 8 weeks after the end of interferon therapy and at 3 months after cryotherapy. The cure was confirmed cytologically at 3 months after clinical reconvalescence (formation of the scarring atrophy area or re-epithelization).
Results: The treatment was effective in 100% (35/35) of the patients from the main group. Twenty nine (82.9%) cases of basalioma required two courses of interferon therapy, 5 (14.3%) cases 3 courses, and one case (2.8%) 4 courses. In the reference group, 94.6% (35/37) of patients were cured. The difference between the proportions of the cured patients between the two groups was 5.4% (confidence interval (CI) -5.2–17.7%). Within the next 3 years of the follow-up there were no relapses in the main group, whereas the relapses were diagnosed in 9 (24.3%) of the patients from the reference group. The difference of the proportions between the two groups was 24.3% (CI 9.6–40%).
Conclusion: Based on the short- and long-term results, the efficacy of intralesional interferon administration in basalioma T2N0M0 was 100%. For tumors of more than 2 cm², an increase of the single and the total cumulative dose of recombinant interferon alfa 2b is necessary, as well as several courses of interferon treatment. Interferon therapy is more effective than cryodestruction based on the 3-year relapse-free survival.
About the authors
A. V. Molochkov
Moscow Regional Research and Clinical Institute (MONIKI)
Email: fake@neicon.ru
MD, PhD, Professor, Deputy Director on Science and International Communications
61/2 Shchepkina ul., Moscow, 129110, Russian Federation
Russian FederationS. A. Rumyantsev
Vologda Regional Clinic for Skin and VenerealDiseases
Email: fake@neicon.ru
MD, Chief Medical Officer
17 M. Ul'yanovoy ul., Vologda, 160000, Russian Federation
Russian FederationA. N. Khlebnikova
M. Sechenov First Moscow State Medical University
Author for correspondence.
Email: alb9696@yandex.ru
MD, PhD, Professor, Chair of Skin and Venereal Diseases, Institute for Professional Education
8/2 Trubetskaya ul., Moscow, 119991, Russian Federation. Tel.: +7 (903) 102 96 96
Russian FederationReferences
- Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, Steijlen PM, Vermeulen A, Neumann H, Kelleners-Smeets NW. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow- up. Lancet Oncol. 2008;9(12): 1149–56. doi: 10.1016/S1470-2045(08)70260-2.
- Fargnoli MC, Peris K. Photodynamic therapy for basal cell carcinoma. Future Oncol. 2015;11(22): 2991–6. doi: 10.2217/fon.15.208.
- Papakostas D, Stockfleth E. Topical treatment of basal cell carcinoma with the immune response modifier imiquimod. Future Oncol. 2015;11(22): 2985–90. doi: 10.2217/fon.15.192.
- Gaspari AA, Sauder DN. Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol Surg. 2003;29(10): 1027–34.
- Cornell RC, Greenway HT, Tucker SB, Edwards L, Ashworth S, Vance JC, Tanner DJ, Taylor EL, Smiles KA, Peets EA. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol. 1990;23(4 Pt 1): 694–700.
- Edwards L, Tucker SB, Perednia D, Smiles KA, Taylor EL, Tanner DJ, Peets E. The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas. Arch Dermatol. 1990;126(8): 1029–32. doi: 10.1001/archderm.1990.01670320053006.
- Kim KH, Yavel RM, Gross VL, Brody N. Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited. Dermatol Surg. 2004;30(1): 116–20.
- Edwards L, Whiting D, Rogers D, Luck K, Smiles KA. The effect of intralesional interferon gamma on basal cell carcinomas. J Am Acad Dermatol. 1990;22(3): 496–500.
- Королева ЛП, Молочков ВА, Хлебникова АН. К эффективности околоопухолевой и вну- триопухолевой интерферонотерапии базалиом. Российский журнал кожных и венерических болезней. 2007;(5): 54–8.
- Хлебникова АН. Новые подходы к лечению базальноклеточного рака кожи на основе интерферонотерапии и криодеструкции. Клиническая дерматология и венерология. 2007;(5): 49–54.
- Петрунин ДД, Оковитый СВ, Косталевская АВ, Сучков СВ. Подходы к иммунокоррекции пациентов с рецидивирующим базально-клеточным раком кожи с различными иммунофенотипами. Вопросы онкологии. 2012;58(3): 406–15.
- Wettstein R, Erba P, Itin P, Schaefer DJ, Kalbermatten DF. Treatment of basal cell carcinoma with surgical excision and perilesional interferon- α. J Plast Reconstr Aesthet Surg. 2013;66(7): 912–6. doi: 10.1016/j.bjps.2013.03.008.
- Fernández-Vozmediano JM, Armario-Hita JC. Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b. J Drugs Dermatol. 2010;9(4): 381–4.
- Chitwood K, Etzkorn J, Cohen G. Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons. Dermatol Surg. 2013;39(9): 1306–16. doi: 10.1111/dsu.12300.
- Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol. 2011;64(2): 413–22. doi: 10.1016/j.jaad.2009.12.013.
- Молочков ВА, Снарская ЕС, Поляков ПЮ, Афонин АВ, Сухова ТЕ, Романко ЮС, Хлебникова АН, Тараней ТА, Королева ЛП, Кладова АЮ, Челюканова МВ, Козлова ЕС. К проблеме лечения базалиом кожи. Российский журнал кожных и венерических болезней. 2005;(6): 4–9.
Supplementary files
